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Abstract: Exercise improves insulin secretion by pancreatic beta cells (β-cells) in patients with type 2
diabetes, but molecular mechanisms of this effect are yet to be determined. Given that contracting
skeletal muscle causes a spike in circulating interleukin-6 (IL-6) levels during exercise, muscle-derived
IL-6 is a possible endocrine signal associated with skeletal muscle to β-cell crosstalk. Evidence to
support a role of IL-6 in regulating the health and function of β-cells is currently inconsistent
and studies investigating the role of IL-6 on the function of β-cells exposed to type 2 diabetic-like
conditions are limited and often confounded by supraphysiological IL-6 concentrations. The purpose
of this study is to explore the extent by which an exercise-relevant concentration of IL-6 influences
the function of pancreatic β-cells exposed to type 2 diabetic-like conditions. Using insulin-secreting
INS-1 832/3 cells as an experimental β-cell model, we show that 1-h IL-6 (10 pg/mL) has no effect on
insulin secretion under normal conditions and does not restore the loss of insulin secretion caused by
elevated glucose ± palmitate or IL-1β. Moreover, treatment of INS-1 832/3 cells to medium collected
from C2C12 myotubes conditioned with electrical pulse stimulation does not alter insulin secretion
despite significant increases in IL-6. Since insulin secretory defects caused by diabetic-like conditions
are neither improved nor worsened by exposure to physiological IL-6 levels, we conclude that the
beneficial effect of exercise on β-cell function is unlikely to be driven by muscle-derived IL-6.
Keywords: pancreatic beta cell dysfunction; insulin secretion; interleukin-6; type 2 diabetes; exercise;
skeletal muscle; electrical pulse stimulation; organ crosstalk
1. Introduction
The pathophysiology of type 2 diabetes (T2D) is incompletely understood, but it is generally accepted
that hyperglycemia occurs only when insulin resistance is combined withβ-cell dysfunction [1]. Defects in
β-cell function are therefore essential to the risk and development of T2D [2]. Finding new therapies
targeted at improvingβ-cell function is thus key to restoring normal blood glucose homeostasis in patients
with T2D.
Exercise is central to the primary care for patients with T2D [3] through its action on slowing the
progression of glucose intolerance [4]. Glucoregulatory benefits of exercise have been attributed to
enhanced insulin sensitivity of peripheral tissues [5] and to improved β-cell function [6,7]. Notably,
exercise also restores β-cell mass in rodent models of both T1D [8] and T2D [9]. Biologically
active compounds released during exercise likely contribute to the protective effects of exercise
in patients with T2D [10,11]. As many of these compounds are released by skeletal muscle [12], it is
currently thought that muscle contraction mediates interorgan crosstalk with distant tissues, including
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β-cells [11]. In this respect, it has been reported that muscle-derived factors (myokines) such as
interleukin-6 are accountable for the protective effects of “muscle-conditioned” medium [13] and
“exercise serum” [14] against proinflammatory-induced β-cell apoptosis.
Although exercise-regulated IL-6 is recognised to lower cytokine-induced loss of β-cell mass [13,14],
specific effects of IL-6 on β-cell function are less convincing and confusing. For example, IL-6 infusion
in mice stimulates [15] and suppresses [16,17] insulin release, while exogenous IL-6 treatment of
cultured insulin-secreting cells and isolated islets increases insulin release in some [18,19] but not
all studies [20]. A better understanding between the interaction of a transient IL-6 response to acute
exercise and its possible effects on β-cell function under diabetic-like conditions is therefore necessary.
In this regard we explored if a direct effect of IL-6 at an exercise-relevant concentration mediates
insulin secretory function of INS-1 832/3 cells under diabetic-like conditions in vitro.
2. Results
2.1. Acute IL-6 Treatment Has No Effect on Glucose-Stimulated Insulin Secretion (GSIS) by INS-1 832/3 Cells
at an Exercise-Relevant Concentration
Exposure of INS-1 832/3 cells to increasing concentrations of IL-6 (0–10,000 pg/mL) has no significant
effect on glucose-stimulated insulin secretion (GSIS) (Figure 1A). That said, at 10,000 pg/mL, IL-6 tends
to lower GSIS, which appears to be a result of suppressed insulin release by INS-1 832/3 cells when
stimulated with 20 mM glucose (Figure 1C). Basal insulin secretion is not significantly affected by
increasing IL-6 (Figure 1B). Importantly, at a concentration of 10 pg/mL (a concentration that better
reflects what is released into circulation following an acute bout of exercise in humans [21]), it appears that
IL-6 has no effect on GSIS by INS-1 832/3 cells (Figure 1). To confirm this lack of effect, in a separate set of
experiments we incubated healthy INS-1 832/3 cells with 10 pg/mL IL-6 for 1 h and then assessed insulin
release at 5 and 20 mM glucose. In healthy INS-1 832/3 cells without IL-6 treatment, insulin secretion is
increased to 6-fold in response to 20 mM glucose (Figure 2A), from 0.5 to 3.0 ng insulin× 10−4 cells/60 min
(Figure 2B). Interestingly, in cells treated with IL-6, insulin secretion is stimulated further by 20 mM
glucose to 8-fold (Figure 2A), from 0.5 to 4.0 ng insulin × 10−4 cells/60 min (Figure 2B). Importantly,
however, this increase in GSIS by cells exposed to IL-6 for 1 h is not statistically significant from control
cells (p = 0.58).
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Figure 1. Dose response of IL-6 on glucose-stimulated insulin secretion. INS-1 832/3 cells were grown 
in fully supplemented RPMI and exposed for 1 h to IL-6 at 0, 1, 10, 100, 1000, or 10,000 pg/mL. The 
rate of insulin secretion was either normalised to basal insulin release (A) or to cell number (B,C) and 
was measured at 5 mM glucose (basal) or 20 mM glucose (stimulated). Data are means ± SEM from 5 
independent experiments with each condition repeated 4–5 times. Statistical significance of mean 
differences was tested by one-way ANOVA. 
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was easured at 5 glucose (basal) or 20 glucose (stimulated). Data are means ± SEM from
5 independent experiments with each condition repeated 4–5 times. Statistical significance of mean
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Int. J. Mol. Sci. 2018, 19, 1924 3 of 13
Int. J. Mol. Sci. 2018, 19, x FOR PEER REVIEW  3 of 12 
 
 
Figure 2. The effect of an exercise-relevant concentration of IL-6 on insulin secretion. INS-1 832/3 cells 
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at 5 mM glucose (basal—black bars) or 20 mM glucose (stimulated—grey bars). Data are means ± SEM 
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mean differences was tested by 2-way ANOVA: asterisks indicate statistically significant differences 
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Figure 2. The effect of an exercise-relevant concentration of IL-6 on insulin secretion. INS-1 832/3 cells
were grown in fully supplemented RPMI and exposed for 1 h to IL-6 (10 pg/mL). The rate of insulin
secretion was either normalized to basal insulin release (A) or to cell number (B) and was measured at
5 mM glucose (basal—black bars) or 20 mM glucose (stimulated—grey bars). Data are means ± SEM
from 4 independent experiments with each condition repeated 4–5 times. Statistical significance of
mean differences was tested by 2-way ANOVA: asterisks indicate statistically significant differences
from equivalent basal glucose conditions (* p < 0.05 and ** p < 0.01).
2.2. Acute IL-6 Treatment Neither Worsens nor Improves Insulin Secretory Function by INS-1 832/3 Cells
Exposed to Diabetic-Like Conditions
Despite the fact that an exercise-relevant concentration of IL-6 has no significant effect in healthy
INS-1 832/3 cells, we next explored to what extent IL-6 may alter insulin secretion by INS-1 832/3
cells pre-exposed to glucotoxic or glucolipotoxic diabetic-like conditions. 48-h exposure of INS-1 832/3
cells to increasing glucose without (Figure 3A) or with palmitate (Figure 3C) has no significant effect
on basal insulin release and is similar in cells treated with IL-6. On the other hand, 48-h exposure to
increasing glucose significantly lowers the amount of insulin secreted by INS-1 832/3 cells in response
to 20 mM glucose (Figure 3B). Insulin secretion in response to 20 mM glucose is further attenuated in
cells pre-exposed to elevated glucose plus BSA-conjugated palmitate (Figure 3D). This loss of insulin
secretory function is unaffected by acute exposure to IL-6 (Figure 3B,D).
In addition to elevated nonesterified fatty acids (NEFAs) and glucose, elevated levels of the
proinflammatory cytokine IL-1β is associated with the pathophysiology of T2D [22]. Moreover, we [21]
and others [13] have recently found that serum conditioned by exercise containing elevated levels of
IL-6 impacts the viability of insulin-secreting cells and pancreatic islets exposed to proinflammatory
cytokines. To examine if this is the case with β-cell function, we exposed INS-1 832/3 cells to IL-1β
for 48 h in the presence and absence of exogenous IL-6 (10 pg/mL) and assessed acute insulin release.
To account for acute IL-6 effects, we also treated INS-1 832/3 cells pre-exposed with IL-1β to IL-6 for 1
h. As expected, 48-h exposure to IL-1β blunts GSIS by INS-1 832/3 cells (Figure 4A). Since basal insulin
release is unaffected by IL-1β (Figure 4B), this significant loss in GSIS is owing to a decreased insulin
secretory response of cells to 20 mM glucose (Figure 4C). IL-1β had similar effects on insulin secretion
in cells co-exposed with IL-6 for 48 h (Figure 4). Moreover, acute IL-6 neither restores nor worsens the
loss of insulin secretion caused by IL-1β (Figure 4). Contrary to reports on cytokine-induced β-cell
apoptosis [23,24], we also failed to provide persuasive support for a protective effect of IL-6 against
IL-1β-induced changes in INS-1 832/3 cell density (Figure 5).
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cells exposed for 48 h t i cre si g glucose 5, 11, or 20 mM in RPMI in the presence (C,D) or absence
of BSA-conjugated palmitate (A,B) were treated with IL-6 (grey bars) or without IL-6 (black bars) for
1 h. IL-6 effects were determined on basal (G5) insulin secretion (A,C) and high glucose (G20) insulin
secretion (B,D) for glucotoxic (A,B) and glucolipotoxic (C,D) cells, respectively. Data are means ± SEM
of 4 independent experiments with each condition repeated 4–5 times. Mean differences were tested
for statistical significance by 2-way ANOVA: asterisks indicate statistically significant differences from
cells cultured in 5 mM glucose (* p < 0.05 and ** p < 0.01).
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It has been suggested that IL-6 from skeletal muscle may act distinctly from IL-6 secreted during 
inflammation by immune cells or adipose tissue [25]. To account for this possibility, we also probed 
the effect of muscle-derived IL-6 on the insulin secretory function of healthy and IL-1β-exposed INS-
1 832/3 cells by using muscle-conditioned medium (CM) from contracting C2C12 muscle myotubes. 
Replicating in vivo effects of exercise [21,26], stimulation of C2C12 myotubes with EPS significantly 
enhances glucose uptake (Figure 6A) and the secretion of IL-6 (Figure 6B). Consistent with previous 
observations shown in Figure 2, 20 mM glucose significantly enhances insulin secretion by INS-1 
832/3 cells incubated with CM (Figure 7A). The effect of glucose on insulin secretion is similar 
regardless of EPS during the medium conditioning (Figure 7A). Coherent with the effects of IL-1β 
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Figure 4. IL-1β induced ef cts in insulin secr re not prevented by IL-6. INS-1 832/3 cells were
exposed for 48 h to 2 ng/mL IL-1β i I ith or without 10 pg/mL IL-6. For acut IL-6 effects,
a separate set of cells pre-exposed to 48 h 2ng/mL IL-1β were treated with 10 pg/mL IL-6 for 1 h
prior to insulin secretion assays. Control cells were incubated in the same media lacking IL-1β. IL-6
effects were determined on GSIS (A), basal (G5) insulin secretion (B), and high glucose (G20) insulin
secretion (C). Data are means ± SEM of 4 independent experiments with each condition repeated 4–5
times. Mean differences were tested for statistical significance by 2-way ANOVA: asterisks indicate
statistically significant differences from control cells without IL-1β (* p < 0.05 and ** p < 0.01).
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Figure 5. IL-1β-induced changes in cell density are not prevented by IL-6. I S-1 832/3 cells ere
exposed for 48 h to 2 ng/mL IL-1β in RPMI with or without 10 pg/mL IL-6 (grey bars). Control
cells were incubated in the same media lacking IL-1β (black bars). IL-6 effects were determined on
cell density as a percentage from equivalent control cells. Data are means SEM of 4 i e e e t
ri ts it c c iti r t ti s. iff r c s r t st f r st tistic l
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2.3. Contraction- ediated Increases in IL-6 from C2C12 yotubes Has No Effect on Insulin Secretion by
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832/3 cells by using muscle-conditioned e i ( f l t es.
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.
shown in Figure 2, 0 mM glucose significantly enhances insul secretion by INS-1 832/3
cells incubated wi h CM (Figure 7A). The effect of glu ose on insulin secretio i similar regardless
of EPS during the medium conditioning (F gure 7A). Coherent wit the effects of IL-1β hown in
Figures 4 and 5, IL-1β has no effect on basal insulin release (Figure 7B), blunts insulin secretion in
response to 20 mM glucose (Figure 7B), and lowers cell density (Figure 7C) of INS-1 832/3 cells exposed
to CM. These IL-1β effects, notably, persist irrespectively of EPS during the medium conditioning
(Figure 7). Our data suggest that a direct effect of IL-6 is unlikely responsible for the improvements in
insulin secretion observed in patients with T2D following exercise and question the validity of IL-6 in
mediating direct β-cell effects in health and disease.
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At physiological concentrations, IL-6 has no significant effect on insulin secretion by INS-1 832/3 
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Figure 6. Electrical pulse stimulation stimulates glucose uptake in C2C12 myotubes and increases
the secretion of IL-6. C2C12 myotubes were exposed with or without 24 h EPS. Effects of EPS
were determined on glucose uptake (A) and IL-6 secretion (B). Data are means ± SEM of 4–9
independent experiments with each condition run in triplicate. Mean differences were tested for
statistical significance by Paired t-test: asterisks indicate statistically significant differences from noEPS
condition (* p < 0.05 and ** p < 0.01).
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i r 7. Conditioned media from “trained” skeletal muscle does not prevent IL-1β-induced decreases
in insulin secretion. INS-1 832.3 cells were exposed with (B) or without (A) 24 h IL-1β combined with
EPS or non-EPS-treated C2C12 muscle-cell conditioned medium. Effects of con itioned edium ± EPS
were determined on basal (G5) insulin secretion (black bars—A,B), high glucose (G20) insulin secretion
(grey bars—A,B), and cell density (C). Data are means ± SEM of 4 independent experiments with
each condition repeated 4–5 times. Mean differences were tested for statistical significance by 2-way
ANOVA: asterisks indicate statistically significant differences from basal glucose condition (* p < 0.05).
3. Discussion
At physiological concentrations, IL-6 has no significant effect on insulin secretion by INS-1 832/3
cells (Figure 1). The finding that IL-6 at low pg/mL concentrations does not impair insulin secretion by
normal INS-1 832/3 cells is of intere t because it has recently come to light that IL-6 may have positive
as well as n gative ffects in β-cells, especially at lower concentrations that mimic those that ar show
to be present in circulation after exercise [18]. Given that IL-6 is secreted by skeletal muscle during
exercise [27] and that both “exercise-conditioned serum” and “muscle-conditioned medium” containing
elevated IL-6 impacts β-cell apoptosis in response to proinflammatory cytokines [13,21], we explored the
effect of an exercise-relevant concentration of IL-6 on β-cell function under diabetic-like conditions.
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3.1. IL-6 Effects on INS-1 832/3 Cells Exposed to Diabetic-Like Conditions
As expected from the typical behavior of native human β-cells, we show that in INS-1 832/3
cells, GSIS is significantly elevated in response to 20 mM glucose (Figure 2). Consistent with
reports in BRIN-BD11 cells and isolated mouse islets [18], we show that acute IL-6 treatment at an
exercise-relevant concentration of 10 pg/mL does not significantly affect GSIS or the amount of insulin
released by INS-1 832/3 cells at 5 or 20 mM glucose (Figure 2). Confirming previous reports by us [28]
and others [29], we show that diabetic-like glucotoxic and glucolipotoxic conditions lowers GSIS from
INS-1 832/3 cells (Figure 3A,D) by lowering the amount of insulin secreted at a stimulatory glucose
concentration (Figure 3C,F). Of interest, insulin secretory defects caused by diabetic-like glucotoxic
and glucolipotoxic conditions (Figure 3) are not restored or exacerbated by acute pre-treatment of
IL-6 (Figure 3). Collectively, these data suggest that a transient IL-6 response at an exercise-relevant
concentration is unlikely associated with regulating insulin secretion from β-cells under healthy or
T2D conditions associated with elevated glucose and/or NEFAs.
In addition to elevated glucose and NEFAs, the pathophysiology of T2D has more recently been
associated with increased inflammation through elevated levels of proinflammatory cytokines [30].
For example, pancreatic islets from T2D patients show increased expression levels of IL-1β. It is also
well established that incubation of pancreatic islets [31] or cultured β-cell lines [32,33] to cytokines
in vitro significantly impairs GSIS. Moreover, prolonged cytokine exposure leads to increased β-cell
apoptosis [34] and is therefore linked with the loss of β-cell mass as well as their functional demise in
T2D. In agreement with previous observations [33], we show that exposure of IL-1β for 48 h completely
blunts GSIS from INS-1 832/3 cells (Figure 4A) by restricting insulin release at a stimulatory glucose
concentration (Figure 4C). Notably, acute IL-6 treatment does not improve the loss of insulin secretory
dysfunction caused by IL-1β (Figure 4). Given that it has been reported previously that prolonged
IL-6 treatment protects against cytokine-induced apoptosis in cultured β-cells and islets [13], we
also co-exposed INS-1 832/3 cells to IL-1β plus IL-6 for 48 h. Unlike the case with apoptosis, IL-6
was unable to prevent the loss of insulin secretory function caused by IL-1β under our conditions
(Figure 4). Differing from reports on cytokine-induced β-cell apoptosis [23,24], we also failed to
provide convincing evidence for the protective effect of IL-6 against IL-1β-induced cell loss (Figure 5).
3.2. Exercise-Induced IL-6 Effects against IL-1β-Induced INS-1 832/3 Cell Dysfunction
Despite failing to provide sufficient evidence for a protective role of IL-6 on the function or
viability of INS-1 832/3 cells in our study, previous reports demonstrating a protective IL-6 effect
against cytokine-induced β-cell apoptosis are convincing [8,13,14]. It is indeed possible that the reason
for this discrepancy is related to the source of IL-6. For example, in the two studies that demonstrate a
conclusive protective IL-6 effect against cytokine-induced apoptosis [13,14], IL-6 was administered to
cells or islets in “exercise-conditioned serum” or “muscle-conditioned medium”. To account for this
disparity, we exposed INS-1 832/3 cells to muscle-conditioned medium collected from C2C12 cells
stimulated with or without EPS in the presence or absence of IL-1β for 24 h. To confirm our model
of exercise using EPS, we show that both glucose uptake by C2C12 cells and secretion of IL-6 are
significantly elevated following EPS (Figure 6). It should be noted, however, that although contraction
mediates a significant increase in IL-6 representing physiology, the absolute concentration of IL-6
from C2C12 conditioned media is nearly 100-fold higher in CM than what would be expected under
physiological conditions in humans. Moreover, CM contains many other myokines in addition to
IL-6 which may impact the function or viability of β-cells [11]. That said, even with such high IL-6
concentrations, conditioned medium collected from contracting C2C12 myotubes neither improved
nor worsened insulin secretory function of INS-1 832/3 cells exposed with (Figure 7B) or without
(Figure 7A) IL-1β. We also show that in the presence of CM, IL-1β has similar effects on cell loss
irrespective of whether the muscle cell medium was conditioned with EPS (Figure 7C). Collectively,
our data suggest that an acute direct improvement in β-cell function by IL-6 is unlikely accountable
for the exercise-induced benefit of β-cell function in patients with T2D [6,7].
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It is worth noting that in our experiments, IL-6 was applied at a physiologically relevant
post-exercise concentration [21,35,36] that is much lower than concentrations of IL-6 typically applied
in vitro. This may explain discrepancies between our data and those published by others [8,23,37].
As our experiments are limited by the use of a single cultured β-cell line, we cannot at this stage exclude
the possibility that IL-6 has functional effects on primary or other β-cell lines or that IL-6 indirectly
mediates insulin secretion by β-cells, via GLP-1, for example, as shown in mice by Ellingsgaard et al.
That being said, a role of IL-6 in mediating positive anti-inflammatory effects in β-cells has not to date
been shown in humans and appears strange given that the action of IL-6 occurs via trans-signaling in
isolated pancreatic islets which is classically related to a proinflammatory response [38]. Furthermore,
plasma IL-6 levels are elevated in patients with metabolic diseases such as obesity and T2D [39], which
are linked to hepatic cell dysfunction and consequent insulin resistance [40]. To further understand
the role of muscle-derived IL-6 during exercise and its possible role in mediating insulin secretion in
humans, further studies are required whereby acute insulin release of healthy and T2D human islets
are examined following exposure to femoral human serum ± exercise in the presence and absence
of IL-6.
4. Materials and Methods
4.1. INS-1E 832/3 Cell Culture
Rat INS-1 832/3 insulinoma cells were maintained in RPMI-1640 medium (GIBCO #11879020)
containing 11 mM glucose, 10% (v/v) fetal bovine serum (FBS), 1 mM sodium pyruvate, 50 U/mL
penicillin, 10 mM HEPES, 50 µg/mL streptomycin, 2 mM GlutaMAX, and 500 µM β-mercaptoethanol.
For experimental conditions, cells were seeded at 1 × 105 cells/well in 96-well microplates with RPMI
as described above but with 5 mM glucose. At 75–85% confluence, cells were treated with RPMI
containing 5, 10, or 20 mM glucose ± BSA conjugated palmitate for 48 h, RPMI containing 5 mM
glucose ± 2 ng/mL IL-1β with or without IL-6 (10 pg/mL) for 48 h, or C2C12 conditioned media ±
EPS containing 5 mM glucose ± 2 ng/mL IL-1β for 24 h. Prior to experiments, INS-1 832/3 cells were
washed into fresh RPMI medium containing 5 mM glucose ± IL-6 (at concentrations stated in figure
legends) for 1 h unless otherwise stated. Palmitate was conjugated to bovine serum albumin (BSA) at a
molar ratio of 7:1, yielding an estimated free fatty acid level of 20 nM, assuming binding parameters
reported by Huber et al. (2006) [41]. FBS was omitted from growth medium for palmitate experiments
and BSA was used as a vehicle control. The cytokines used in this study were from rat and purchased
from R&D systems (Minneapolis, MN, USA).
4.2. Insulin Secretion
INS-1 832/3 cells seeded and exposed to treatments as described above were washed into warm
(37 ◦C) Krebs-Ringer HEPES (KRH) buffer comprising 135 mM NaCl, 3.6 mM KCl, 10 mM HEPES
(pH 7.4), 0.5 mM MgCl2, 1.5 mM CaCl2, 0.5 mM NaH2PO4, 2 mM GlutaMAX, 5 mM glucose, and
0.2% (w/v) BSA. After 1 h, cells were washed into fresh KRH and incubated under air at 37 ◦C for
60 min with continuous shaking at 250 rpm. Next, supernatants were collected on ice and replaced
with KRH containing 20 mM glucose. After another 60-min incubation, supernatants were collected
on ice. Supernatants were assayed for insulin by homogenous time-resolved fluorescence (#62IN1PEG,
Cisbio Bioassays, Codolet, France). Secreted insulin was normalised to cell density (see below).
4.3. Muscle-Conditioned Medium
Mouse skeletal muscle C2C12 myoblasts (CRL-1772) were maintained in Dulbeccos’s Modified
Eagles Medium (DMEM: GIBCO #11966025) containing 5 mM glucose, 10% (v/v) fetal bovine serum
(FBS), 1 mM sodium pyruvate, 100 U/mL penicillin, 100 µg/mL streptomycin, and 1 mM GlutaMAX.
For differentiation to myotubes, cells were seeded in 6-well microplates at a density of 2× 105 cells/well
and, at 85–95% confluence, washed into fresh DMEM containing 5 mM glucose, 2% (v/v) horse serum,
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1 mM sodium pyruvate, 100 U/mL penicillin, 100 µg/mL streptomycin, and 1 mM GlutaMAX
(differentiation medium). Differentiation medium was replaced daily until myotubes had formed.
Visual inspection using an inverted light microscope indicated that complete differentiation took
5 days. Cell passages between 8 and 15 were used for experimentation. After 5 days of differentiation,
myotubes were washed into fresh DMEM differentiation culture medium (described above) and
treated for 24 h with or without electrical pulse stimulation (EPS: 11.5V, 1 Hz, using 2 milliseconds
pulses; C-Pace EP, IonOptix, Westwood, CA, USA). In cells treated with EPS, muscle contraction was
confirmed by visual inspection using an inverted light microscope. The EPS protocol used for our
experiments is based on exercise training models developed in C2C12 cells [12] and mimics aspects
of muscle contraction, for example, increased IL-6 secretion and enhanced 2-deoxyglucose glucose
uptake. After 24 h, myotube-conditioned culture medium ± EPS was collected, filter-sterilised using
0.45 µM millipore syringe filters, and stored at −80 ◦C until used for crosstalk experiments with INS-1
832/3 cells.
4.4. Glucose Uptake
2-Deoxyglucose (2DG) uptake was measured as described previously by [42]. Briefly, C2C12
myotubes treated with or without EPS for 24 h (cf. 2.3) were washed and incubated in serum-free
DMEM medium supplemented with 5 mM glucose, 1 mM sodium pyruvate, 100 U/mL penicillin,
100 µg/mL streptomycin, and 1 mM GlutaMAX for 2 h at 37 ◦C. Cells were then incubated for 20 min
in the Krebs-Ringer bicarbonate buffer containing 115 mM NaCl, 4.7 mM KCl, 10 mM HEPES, 1.2 mM
MgSO4, 1.28 mM CaCl2, 1.2 mM KH2PO4, 24 mM NaHCO3, 0.1% BSA, and 1 mM 2-DG. Subsequently,
cells were washed twice with phosphate-buffered saline and lysed via agitated incubation in the
presence of 0.1 N NaOH for 10 min at 65 ◦C and a further 50 min at 85 ◦C. Lysates were solubilised
with 0.1 N HCl and then incubated, whilst shaking, for 10 min at room temperature in 200 mM
triethanolamine, pH 8. Lysates were transferred to a 96-well plate containing assay medium with
50 mM triethanolamine (pH 8), 50 mM KCl, 15 U/mL glucose-6-phosphate dehydrogenase, 0.2 U/mL
diphorase, 0.1 mM NADP, 0.02% (w/v) BSA, and 2 µM resazurin (Invitrogen, Carlsbad, CA, USA).
This reaction mixture was incubated at 37 ◦C for 60 min to allow 2DG-dependent reduction of resazurin
to the fluorescent resorufin (λex/em = 540/590 nm), which was detected using a FLUOstar Omega plate
reader (BMG Labtech, Offenburg, Germany). Glucose uptake was normalised to protein concentration
as determined using the Bradford protein assay (Bio-Rad, Hercules, CA, USA).
4.5. IL-6 Secretion
IL-6 was measured in conditioned medium collected from resting or contracting C2C12 skeletal
muscle myotubes (cf. 2.3). Aliquots of conditioned media were assayed for secreted IL-6 by
homogenous time-resolved fluorescence (#63ADK043PEB, Cisbio Bioassays, Codolet, France) using
the manufacturer’s instructions.
4.6. Cell Density
Density of attached cells was determined in 96-well plates by 4′,6-diamidino-2′-phenylindole
dihydrochloride (DAPI) fluorescence [43]. Cells seeded and treated as described in the “insulin
secretion” section were washed with phosphate-buffered saline (PBS) and fixed in 4% (v/v)
paraformaldehyde (ThermoFisher Scientific (Waltham, MA, USA), #28908). After fixation, cells were
washed again in PBS and then loaded with 0.5 µg/mL DAPI. To limit background detection after
loading with DAPI, cells were washed 4 times with PBS. DAPI fluorescence (λex/em = 350/460 nm) was
detected using a FLUOstar omega plate reader (BMG Labtech, Offenburg, Germany ) in fluorescence
intensity, bottom-reading, and well-scanning mode.
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4.7. Statistical Analysis
Significance of mean differences was tested for by paired t-tests (Figure 6) and one-way (Figure 1)
or two-way (all other figures) ANOVA applying Fisher’s LSD post hoc analysis using GraphPad Prism
Version 7.0 for Mac OS X (GraphPad software, San Diego, CA, USA). Data are presented as means± SEM.
5. Conclusions
Our data deepen the understanding of the link between IL-6 and glucose-stimulated insulin
secretion in β-cells under healthy and diabetic-like conditions. We show that at an exercise-relevant
concentration, IL-6 neither alleviates nor exacerbates β-cell failure and is therefore unlikely to mediate
direct crosstalk effects between skeletal muscle and β-cells under diabetic-like conditions.
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